0000000000085645

AUTHOR

Wagner A

showing 4 related works from this author

Three-prong τ decays with charged kaons

1998

Final states with charged kaons in three-prong τ decays are studied by exploiting the particle identification from the dE/dx measurement. The results are based on a sample of about 1.6 × 105 detected τ pairs collected with the ALEPH detector between 1991 and 1995 around the Z peak. The following branching ratios have been measured: B(τ- → K−K+π−ντ) = (1.63 ± 0.21 ± 0.17) × 10−3, B(τ− → K−π+π−ντ) = (2.14 ± 0.37 ± 0.29) × 10−3, B(τ− → K−K+π−π0ντ) = (0.75 ± 0.29 ± 0.15) × 10−3, and B(τ− → K−π+π−π0ντ) = (0.61 ± 0.39 ± 0.18) × 10−3. The first two measurements are more precise than the current world averages, while the last two channels are investigated for the first time. The 95% C.L. upper limi…

PhysicsSystematic errorTime projection chamberPhysics and Astronomy (miscellaneous)010308 nuclear & particles physicsBranching fractionHigh Energy Physics::PhenomenologySettore FIS/01 - Fisica SperimentaleVECTOR01 natural sciencesMESONSParticle identificationPHYSICS0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]High Energy Physics::ExperimentAtomic physics010306 general physicsEngineering (miscellaneous)Particle Physics - Experiment
researchProduct

A study of tau decays involving eta and omega mesons

1997

The 132 pb(-1) of data collected by ALEPH from 1991 to 1994 have been used to analyze eta and omega production in 7 decays. The following branching fractions have been measured: B(tau(-) --> nu(tau)omega h(-)) = (1.91 +/- 0.07 +/- 0.06) x 10(-2), B(tau(-) --> nu(tau)omega h(-)pi(0)) = (4.3 +/- 0.6 +/- 0.5) x 10(-3), B(tau(-) --> nu(tau)eta K-) = (2.9(-1.2)(+1.3) +/- 0.7) x 10(-4), B(tau(-) --> nu(tau)eta(h)(-)pi(0)) = (1.8 +/- 0.4 +/- 0.2) x 10(-3) and the 95% C.L. limit B(tau(-) --> nu(tau)eta pi(-)) < 6.2 x 10(-4) has been obtained. The omega pi(-) and eta pi(-)pi(0) rates and dynamics are found in agreement with the predictions made from e(+)e(-) annihilation data with the help of isospi…

PhysicsParticle physicsAnnihilationPhysics and Astronomy (miscellaneous)Meson[PHYS.HEXP] Physics [physics]/High Energy Physics - Experiment [hep-ex]010308 nuclear & particles physicsElectron–positron annihilation01 natural sciencesOmegaIsospin0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsParticle Physics - ExperimentLepton
researchProduct

Liraglutide and Renal Outcomes in Type 2 Diabetes.

2017

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…

MaleSettore MED/09 - Medicina InternaAcute Kidney Injury; Aged; Albuminuria; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kidney Failure Chronic; Liraglutide; Male; Middle AgedType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesGLOMERULAR-FILTRATION-RATEKIDNEY-FUNCTIONDISEASElaw.inventionKidney Failurechemistry.chemical_compound0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawMedicineDiabetic NephropathiesHypoglycemic Agents.Settore MED/49 - Scienze Tecniche Dietetiche ApplicateChronicRISKKidneyAcute kidney injury11 Medical And Health SciencesGeneral MedicineAcute Kidney InjuryMiddle AgedIntention to Treat Analysismedicine.anatomical_structureCreatinineTRIALFemaleliraglutide randomized controlled trial type 2 diabetes renal outcomesLife Sciences & BiomedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyRenal function030209 endocrinology & metabolismCARDIOVASCULAR OUTCOMESFollow-Up Studie03 medical and health sciencesMedicine General & InternalDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicineDiabetes MellitusAlbuminuriaHumansHypoglycemic AgentsIntensive care medicineAgedCreatinineScience & Technologybusiness.industryLiraglutideMORTALITYLiraglutidemedicine.diseaseINTENSIVE GLUCOSE CONTROLINDIVIDUALSDiabetes Mellitus Type 2chemistryDiabetic NephropathieKidney Failure ChronicLEADER Steering Committee and InvestigatorsbusinessFollow-Up Studies
researchProduct

A Method to Extract the Complete Fiber Network Topology of Planar Fibrous Tissues and Scaffolds.

2010

Improving fabrication protocols and design strategies, investigating on how scaffold architecture affects cell morphology, metabolism and phenotypic expression, predicting mechanical behaviors, have increasingly become crucial goals in the development of engineered tissue scaffolds. In the present study, an image-based analysis approach that provides an automatic tool to fully characterize engineered tissues fiber network topology was developed. The following micro architectural features are detected: fiber angle distribution, fiber connectivity, fiber overlap spatial density, fiber diameter. In order to demonstrate the potential of this approach Electrospun poly(ester urethane)urea (ES-PEU…

soft tissue engineering scaffold morphology image analysis
researchProduct